Veritable’s Passage Bio PASG Stock Holding History

Veritable’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,152	Closed	-$21.7K	–	576
2023 Q2	$21.7K	Hold	1,152	–	–	﹤0.01%	886
2023 Q1	$22.1K	Buy	+1,152	New	+$31.2K	﹤0.01%	888

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Veritable's PASG Position: Q3 2023 in Review

Veritable sold out of Passage Bio (PASG) in Q3 2023, closing a stake of 1,152 shares — an estimated $21.7K sold.

Veritable first reported a position in PASG in Q1 2023 and held it in 2 quarters. The position peaked at $22.1K in Q1 2023. 48 funds tracked by Wall St. Rank hold PASG as of Q3 2023.

Veritable reported no remaining Passage Bio position as of Q3 2023 after selling out during the quarter.
Veritable sold 1,152 Passage Bio shares in Q3 2023, an estimated $21.7K.
Veritable first reported a position in Passage Bio in Q1 2023 and held it in 2 quarters.
Veritable's Passage Bio position peaked at $22.1K in Q1 2023.
48 funds tracked by Wall St. Rank held Passage Bio as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.